Stock Performance and Market Context
The stock’s new low of Rs.15.8 represents a notable drop from its 52-week high of Rs.28.8, reflecting a year-long decline of 21.56%. This contrasts sharply with the broader Sensex index, which has delivered a positive return of 7.88% over the same period. Despite outperforming its sector by 2.96% on the day, Bharat Immunological remains well below its key moving averages, trading beneath the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained downward momentum.
On the broader market front, the Sensex experienced a volatile session, recovering from an initial gap down of 1,710.03 points to close at 78,731.58, down 1.88%. Notably, other indices such as NIFTY REALTY and S&P Bse Realty also hit new 52-week lows, indicating sector-specific pressures in certain segments of the market.
Financial Metrics and Fundamental Assessment
Bharat Immunological & Biological Corporation Ltd’s financial health continues to raise concerns. The company has not declared results in the past six months, contributing to uncertainty around its current standing. Over the last five years, the company’s net sales have contracted at an annualised rate of -24.67%, while operating profit has deteriorated sharply by -170.32%. This prolonged decline in core financial metrics has weighed heavily on investor sentiment.
The company’s debt servicing capacity is also under strain, with a Debt to EBITDA ratio of -1.00 times, indicating a negative EBITDA relative to debt levels. The half-yearly debt-to-equity ratio has surged to 83.16%, the highest recorded, underscoring the elevated leverage risk.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Recent Quarterly Results and Cash Flow Trends
The company’s latest reported figures for the nine months ended September 2023 reveal a sharp contraction in net sales, which declined by 87.03% to ₹76.5 million. Operating cash flow for the year has been reported at ₹0 million, marking the lowest level in recent history and highlighting liquidity pressures. These figures contribute to the overall weak long-term fundamental strength, as reflected in the downgrade of the company’s Mojo Grade from Sell to Strong Sell on 9 April 2024, with a current Mojo Score of 3.0.
Comparative Performance and Risk Assessment
Over the past year, Bharat Immunological’s stock has generated a negative return of 21.56%, while profits have fallen by 42.4%. The stock has underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months. This underperformance, combined with the company’s elevated debt levels and declining sales, positions the stock as a higher-risk holding within the Pharmaceuticals & Biotechnology sector.
Why settle for Bharat Immunological & Biological Corporation Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Technical Indicators and Moving Averages
From a technical standpoint, Bharat Immunological’s share price remains below all key moving averages, including the short-term 5-day and 20-day averages as well as the longer-term 50-day, 100-day, and 200-day averages. This persistent weakness in price action suggests a lack of upward momentum and continued selling pressure. The stock’s relative underperformance compared to the sector and broader market indices further emphasises the challenges it faces in regaining investor confidence.
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector has experienced mixed performance recently, with some indices such as NIFTY REALTY and S&P Bse Realty also hitting 52-week lows today. While the Sensex remains below its 50-day moving average, the 50DMA is still trading above the 200DMA, indicating some underlying resilience in the broader market despite sector-specific pressures.
Summary of Key Financial and Market Metrics
To summarise, Bharat Immunological & Biological Corporation Ltd’s stock has reached a new 52-week low of Rs.15.8, reflecting a year-long decline of 21.56% against a positive Sensex return of 7.88%. The company’s financial profile is marked by declining sales, negative operating cash flow, and elevated leverage, with a Debt to EBITDA ratio of -1.00 times and a debt-to-equity ratio of 83.16%. The downgrade to a Strong Sell Mojo Grade and a Mojo Score of 3.0 further underline the stock’s current standing within the Pharmaceuticals & Biotechnology sector.
These factors collectively illustrate the challenges Bharat Immunological faces in its current market environment, with the stock’s technical and fundamental indicators signalling continued caution.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
